MK-677 (Ibutamoren) vs Tirzepatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

MK-677 (Ibutamoren)

MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.

Full details →

Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Full details →

Side-by-Side Comparison

AspectMK-677 (Ibutamoren)Tirzepatide
MechanismActs as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects.Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.
Typical DosageTypical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase.Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.
AdministrationOral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing.Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.
Side EffectsIncreased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity.Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.
Best For

What They Have in Common

Both MK-677 (Ibutamoren) and Tirzepatide are commonly used for:

Key Differences

Ready to Learn More?